Facio screens 34,000 compounds


Leiden, the Netherlands - December 28, 2016

Facio Therapies announced today that it has screened approximately 34,000 compounds for their ability to repress the production of the muscle-toxic DUX4 protein in cultured muscle cells derived from FSHD patient biopsies. As planned, a variety of compounds with the desired effect (known as “hits”) have been identified. In September 2016, Facio announced that, together… read more

Facio presents its business approach at the Dutch Life Sciences Conference


Leiden, the Netherlands - November 17, 2016

Facio Therapies will present its business approach at the Dutch Life Sciences Conference in Leiden, the Netherlands, on November 24th, 2016. Facio’s single goal is to develop a causal therapy for facioscapulohumeral dystrophy (FSHD), a devastating muscle wasting disease that affects over 700,000 people worldwide. With active support from the global FSHD community, Facio is… read more

Growing FSHD community support for Facio


Leiden, the Netherlands - November 14, 2016

Facio Therapies announced today that the Dutch FSHD Foundation (FSHD Stichting) and the FSHD Canada Foundation have joined its shareholder base, which already included the FSHD Global Research Foundation and FSHD-affected families. New and existing investors together provided over €865,000 (about US$960,000) in new equity funding. Facio’s Chairman, Kees van der Graaf, noted that to… read more

Facio presents FSHD drug discovery progress at the World Orphan Drug Congress


Leiden, the Netherlands - November 9, 2016

Facio Therapies will present its progress in facioscapulohumeral dystrophy (FSHD) drug discovery at the World Orphan Drug Congress Europe in Brussels, Belgium, on November 17th, 2016. The World Orphan Drug Congress Europe provides a networking platform for all stakeholders in the rare disease industry, including pharma, biotechs, investors, payers, regulators, and patient advocates. In a Pitch… read more

Facio develops breakthrough tool for FSHD drug discovery


Leiden, the Netherlands - August 31, 2016

Facio Therapies has established the first-ever validated platform that enables screening large numbers of compounds for their ability to repress the production of the DUX4 protein in cultured muscle cells derived from FSHD patient biopsies. With this tool, Facio expects to identify series of compounds with the desired effect before the end of 2016. Facio’s… read more

FSHD Unlimited publishes its first Annual Report


Leiden, the Netherlands - June 27, 2016

Facio provides updates on operational progress and financial results FSHD Unlimited, the parent company of both Facio Therapies and Facio Intellectual Property, has published its first audited Annual Report, which covers the period of September 2014 (inception) through December 2015. Having raised €2,475,000 in equity, the Facio group of companies ended the report period with… read more

Facio presents at AMIS FSH patient meeting


Leiden, the Netherlands - March 16, 2016

Facio Therapies is invited to present at the AMIS FSH patient meeting in Lyon, France on March 19th, 2016. This patient meeting is organized by the French FSHD patient organization AMIS FSH, member of the European consortium FSHD Europe. The program of this spring summit features daily care for people with FSHD, the future of FSHD research… read more

Facio presents at Friends of FSH Research Summit


Leiden, the Netherlands - February 26, 2016

Facio Therapies will present at the Friends of FSH Research Summit, which will be held on February 29th and March 1st, 2016 in Portland, Oregon USA. This leap year summit brings together leading academics in the FSHD field, industry leaders and drug regulators to discuss the key therapeutic strategies for FSHD and in particular how to… read more

Facio obtains funding from the Dutch FSHD Foundation


Leiden, the Netherlands - February 24, 2016

Facio Therapies has received support from the FSHD Stichting(“Dutch FSHD Foundation”) for a total of €100,000 (about 110,000 USD) for its drug discovery program towards a causal therapy for FSHD.  Facio will use the proceeds from this convertible loan for its ongoing drug discovery program. This program is running in close collaboration with partner Evotec and aims… read more

Facio strengthens its Board


Leiden, the Netherlands - February 10, 2016

Facio Therapies announces that Otto Postma has been appointed to the Board of FSHD Unlimited as per February 11, 2016. FSHD Unlimited is the parent company of both Facio Therapies and Facio Intellectual Property. Its shareholders have unanimously approved the nomination of Otto Postma for membership of the Board. With his appointment, the Board now consists… read more